Why Weight Loss Drugs Benefit the Brain

Metabolic dysfunction is characterized by insulin resistance and chronically high blood glucose levels and is a hallmark of neurodegenerative diseases. 
 

People with obesity or diabetes have up to twice the lifetime risk of Alzheimer's disease and dementia compared to people without these conditions. Having high blood glucose levels, even in the absence of diabetes, elevates one's risk of neurodegenerative diseases by 18% compared to having normal blood glucose levels.
 

Glucagon-like peptide (GLP) is known as an incretin, which is a hormone produced in the gut that stimulates the secretion of insulin after we eat food. 

Because people with diabetes have trouble producing (in the case of type 1 diabetes) or responding to (in the case of type 2 diabetes) insulin, drugs that simulate GLP's actions can help with blood glucose regulation in the body and brain. They do this by increasing the expression of glucose transporters at the blood-brain barrier and throughout the body—enhancing glucose uptake and energy metabolism.
 

However, enhanced energy metabolism might only be one part of the story. Recent research points to the following mechanisms of GLP-1RAs that explain their neuroprotective potential.
 

• They reduce neuroinflammation: Neuroinflammation, characterized by chronic activation of glial cells and production of inflammatory molecules, is a key hallmark of neurodegenerative diseases and can be triggered by protein aggregates. It's also linked to brain insulin resistance. Incretin hormones have anti-inflammatory properties, primarily mediated through neuronal GLP-1R activation. GLP-1 mimetics can increase anti-inflammatory biomarkers in microglia and suppress the NLRP3 inflammasome, which is overactive in many neurodegenerative conditions. Dampening neuroinflammation can disrupt the cycle where inflammation exacerbates protein aggregation.
• They promote synaptic plasticity and neurogenesis: Preclinical studies suggest incretin receptor agonism can promote synaptic plasticity and potentially neurogenesis. Treatment with incretin analogues has been shown to increase levels of neurotrophic factors like BDNF, which support neuroplasticity and neuroprotection. Improvements in long-term potentiation, important for memory, have also been observed.
• They protect against neuronal excitotoxicity and cell death: Neurodegenerative diseases involve neuronal injury and death, sometimes due to overstimulation (excitotoxicity). GLP-1R agonism can attenuate this damage. Incretin therapies protect against apoptosis by increasing antiapoptotic signaling molecules and decreasing proapoptotic ones. Protecting neurons from death helps preserve brain function.
• They enhance glymphatic system function: The glymphatic system helps clear neurotoxic waste products like amyloid-β and tau, and its function is impaired in neurodegenerative diseases. GLP-1R agonism has been reported to alter the expression and function of aquaporin 4, a protein crucial for glymphatic transport, potentially promoting the clearance of toxic substances that accumulate in the brain and cause dysfunction and neurodegeneration.

Final thoughts

Semaglutide and other GLP-1 drugs have powerful metabolic and cardiovascular benefits, but their long-term safety profile is nuanced and demands vigilance. For example, using these medications has been associated with an increase in the risk of serious gastrointestinal events like pancreatitis and bowel obstruction; gallbladder and biliary disease, diabetic retinopathy, and even thyroid cancer. They've been shown to elevate resting heart rate by as much as 2–4 beats per minute, and without dedicated resistance training and adequate protein intake, they elevate the loss of lean mass and compromise bone mineral density.

These findings are signals and don't implicate GLP-1 medications as causal of any disease—but they do warrant caution.

Thanks to their ability to enhance insulin signaling, curb inflammation, and protect brain cells, GLP-1RAs also hold significant potential in mitigating neurodegenerative diseases. While these therapies effectively regulate blood glucose—a critical factor in safeguarding brain health—this same goal can also be pursued through accessible, everyday choices. 

For instance, a diet high in fiber and low in processed sugars stabilizes blood glucose, while regular exercise enhances insulin sensitivity. Similarly, time-restricted eating aligns eating patterns with the body’s natural rhythms, promoting metabolic health. Together, these strategies echo the benefits of GLP-1RAs, reducing inflammation and supporting neuronal resilience. 

As research into GLP-1RAs advances, let’s not overlook the profound impact of diet, exercise, quality sleep, and time-restricted eating, habits that can build a stronger defense against neurodegenerative diseases and nurture our brains for the long haul.

I outlined how powerful these three lifestyle pillars are in episode #96: How to Improve Metabolic Health with HIIT, Circadian-Timed Eating, & Sleep.

I go in depth on GLP-1 medications, their benefits, and their potential risks and side effects in Premium Member Q&A Session #66. A few hand-picked timestamps:

• (3:00) Do GLP-1 drugs actually work for weight loss?
• (5:18) Are these weight-loss medications safe for people without diabetes?
• (9:01) Could drugs like Ozempic help treat arthritis?
• (11:14) Cardiovascular benefits linked to GLP-1 therapy
• (13:00) Do these medications offer protection for the brain?
• (14:03) Potential for slowing Alzheimer's disease progression
• (15:32) Semaglutide vs. other diabetes drugs for Alzheimer's risk reduction
• (17:32) Could these weight-loss drugs help treat addiction?
• (18:22) Exploring GLP-1 receptor agonists as cancer prevention agents
• (20:01) Is muscle loss a real concern?
• (22:16) Do these treatments negatively affect bone density?